ArticleCanadian liver journal2026
Cardiometabolic comorbidity and health outcomes of persons with metabolic dysfunction-associated steatotic liver disease (MASLD) in Ontario, Canada.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to describe the prevalence of cardiometabolic disease and clinical outcomes of persons with metabolic dysfunction-associated steatotic liver disease (PwMASLD). Methods: PwMASLD in Ontario, Canada, were identified using administrative data sets between January 1, 2013, and December 31, 2021, and followed until December 31, 2022. PwMASLD were categorized into three mutually exclusive subgroups: (a) Results: Data from 18,202 PwMASLD and 72,770 controls were analyzed. The mean age of PwMASLD was 53.4 years, 56% were female, and 88% resided in an urban area. Of these, 12,729 (70%), 2,675 (15%), and 2,798 (15%) were in the MASLD-only, MASH, and cirrhosis subgroups, respectively. Cardiovascular disease, type 2 diabetes, and hypertension were higher in PwMASLD versus controls. Liver- (29.2% versus 1.4%) and cardiovascular-related (16.8% versus 6.6%) health outcomes were also greater in PwMASLD. PwMASLD with cirrhosis had the highest burden of comorbidities, followed by MASH and MASLD-only subgroups. The cirrhosis subgroup had the highest rates of cardiovascular- and liver-related outcomes. Conclusions: PwMASLD in Ontario had more comorbidities and poorer health outcomes than controls. PwMASLD with cirrhosis showed the highest burden of disease versus those with MASH or MASLD alone. To ensure effective MASLD management, early identification of advanced disease and access to interventions to delay or prevent its progression must be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.